By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panelists generally agreed that Abbott's MiniMed deal is a positive incremental step but not a significant catalyst for the company's stock. They expressed concerns about the long timeline for US FDA approval, competition in the glucose monitoring market, and potential margin pressure from the dual-analyte sensor.
Risk: The single biggest risk flagged was the long timeline for US FDA approval and potential reimbursement friction in Europe, which could mute early adoption data and slow pressure on FDA timelines.
Opportunity: The single biggest opportunity flagged was the potential for high European adoption of the dual-analyte sensor, which could provide some upside despite the murky near-term catalysts.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Abbott Laboratories (NYSE:ABT) is a deep value stock to invest in now. On June 3, Abbott Laboratories (NYSE:ABT) entered into an expanded agreement with MiniMed. The two are joining forces to commercialize dual glucose-ketone sensors for integration with MiniMed smart dosing systems.
Pressmaster/Shutterstock.com
The monitoring sensors under commercialization are designed to enable real-time detection of rising ketone levels. Consequently, they are able to prevent diabetic ketoacidosis, a complication known for hundreds of thousands of hospitalizations in the US. The agreement builds on Abbott Laboratories and MiniMed’s existing partnership for the Instinct sensor.
While Abbott boasts of glucose-ketone systems, they are not yet cleared or available for sale in the US. Nevertheless, they have already received the European Union CE mark while undergoing FDA review. The mark covers the first dual-analyte sensor that measures glucose and ketones, designed to help people manage diabetes and detect rising ketone levels. The company plans to launch the systems in some European countries before the year’s end.
Abbott Laboratories (NYSE:ABT) is a dividend king, having increased payouts for 50 consecutive years. With an annualized dividend of $2.52, the stock yields about 2.7%. In May, the company paid a quarterly dividend of $0.63 a share.
Abbott Laboratories (NYSE:ABT) is a global healthcare company that researches, develops, and manufactures medical devices, diagnostic tests, nutritional products, and branded generic pharmaceuticals. They focus on helping people live healthier lives through innovative technology spanning the entire continuum of care.
While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Debt-Free IT Stocks to Buy Now and 10 Best Stocks to Buy According to Billionaire Bill Gates.
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"The partnership is a small European option, not evidence that ABT is deep value."
The MiniMed deal gives Abbott a first-mover CE-marked dual glucose-ketone sensor for Europe by year-end, extending its existing Instinct partnership into ketoacidosis prevention. Yet the article omits that US launch remains years away pending FDA review, that ABT already trades at roughly 24x forward earnings with modest mid-single-digit organic growth, and that the piece pivots to pushing unrelated AI names. Dividend-king status is real but already priced in. The announcement is incremental portfolio expansion rather than a re-rating catalyst.
European early adoption could accelerate real-world data and pressure the FDA timeline, turning a modest product into a durable share-gain story against Dexcom.
"Near-term value hinges on US FDA clearance and payer adoption for the glucose-ketone sensors; EU launch alone offers limited earnings visibility, so the 'deep value' label may be premature without a clear US-path catalyst."
Abbott's expanded MiniMed glucose-ketone sensor collaboration signals optionality in ABT's devices/Dx franchises, but the near-term catalysts are murky. EU CE mark progress provides some upside, yet US FDA clearance and subsequent payer adoption remain significant swing factors that could push or delay revenue realization by years. ABT's dividend king status (yield ~2.7%) supports a value narrative, but without a clear US path or sizable margin contribution, the stock may not re-rate quickly. The mix of regulatory risk, competition in glucose monitoring, and integration execution suggests upside is uncertain and longer-dated, not a slam-dunk near-term win.
EU clearance alone isn't enough—the real test is US FDA clearance and reimbursement; without a timely US path, the value thesis could easily falter.
"Abbott is a high-quality compounder, but calling it a 'deep value' stock ignores its current premium valuation multiple relative to historical averages."
Labeling Abbott Laboratories (ABT) as a 'deep value' stock is a stretch. Trading at roughly 25x forward earnings, it is priced as a premium compounder, not a value play. The MiniMed partnership is a positive incremental step for their FreeStyle Libre ecosystem, but it is hardly a needle-mover for a $200B+ market cap company. The real story here is the moat surrounding their continuous glucose monitoring (CGM) franchise. While the dual-analyte sensor is innovative, the growth narrative is already priced in. Investors should focus on the diagnostic segment's post-COVID normalization rather than just the dividend history to justify the current valuation multiple.
If the FDA delays the dual-analyte sensor approval or if competitive pressure from Dexcom’s G7 and Stelo erodes ABT's CGM market share, the current premium multiple will face a significant contraction.
"The glucose-ketone sensor is a legitimate pipeline asset, but the article's 'deep value' thesis is unsupported by ABT's current valuation and undermined by the author's own pivot to recommending unnamed alternatives."
The article conflates two separate narratives: a legitimate product milestone (dual glucose-ketone sensor with EU CE mark) and a valuation claim ('deep value'). The sensor is real but not yet revenue-generating—it's in FDA review with European launch targeted for year-end. ABT's 2.7% yield and 50-year dividend streak are genuine, but neither justifies 'deep value' without knowing the current multiple. At ~28x forward P/E (vs. healthcare median ~18x), ABT trades at a premium, not a discount. The article provides zero valuation support for its headline claim, then pivots to dismissing ABT in favor of unnamed AI stocks—a red flag for credibility.
If the dual-sensor FDA approval clears in H2 2024 and European uptake exceeds expectations, ABT could see meaningful diabetes-care revenue acceleration that justifies current multiples; the 50-year dividend history also signals genuine operational stability that pure-play medtech peers lack.
"Dividend stability creates a valuation floor that supports ABT's multiple through regulatory waits."
Gemini flags the premium multiple accurately but underplays how Claude's point on 50-year dividend stability could limit downside during FDA delays. That operational consistency gives ABT a floor pure-play CGM names lack, even at 25x. The unmentioned risk is post-approval reimbursement friction in Europe, which could mute early adoption data and slow any pressure on FDA timelines.
"Valuation hinges on payer adoption and US uptake, not CE clearance or dividend history."
Claude points to valuation and dividend as legitimacy, but the real driver is payer economics and US adoption. CE clearance alone doesn’t guarantee revenue; even with FDA clearance, reimbursement timetables and price ceilings in major markets can cap upside. Dexcom competition and post-launch real-world uptake will likely keep ABT’s multiple under pressure unless cash flow accelerates meaningfully. The article glosses over that risk—valuation is still a bet on adoption, not just approvals.
"The increased manufacturing complexity of dual-analyte sensors threatens to compress Abbott’s gross margins despite potential revenue growth."
Gemini and Claude correctly identify the premium valuation, but you are all ignoring the margin-dilutive nature of dual-analyte sensors. Integrating ketone monitoring into the Libre platform increases manufacturing complexity and COGS (cost of goods sold) per unit. Even if European adoption is high, Abbott’s gross margins could face compression before scale is achieved. The market is pricing this as a revenue growth story while ignoring the potential bottom-line drag from hardware integration costs.
"Manufacturing complexity is real, but payer pricing power poses a larger margin risk than COGS integration."
Gemini's COGS compression risk is material but needs quantification. Abbott's Libre gross margins are ~75%; dual-analyte adds complexity, but ketone strips are lower-cost than glucose. The real margin pressure comes post-FDA if payers demand bundled pricing against Dexcom G7. That's a reimbursement problem, not an engineering one. Without US adoption timeline clarity, margin forecasts are premature.
The panelists generally agreed that Abbott's MiniMed deal is a positive incremental step but not a significant catalyst for the company's stock. They expressed concerns about the long timeline for US FDA approval, competition in the glucose monitoring market, and potential margin pressure from the dual-analyte sensor.
The single biggest opportunity flagged was the potential for high European adoption of the dual-analyte sensor, which could provide some upside despite the murky near-term catalysts.
The single biggest risk flagged was the long timeline for US FDA approval and potential reimbursement friction in Europe, which could mute early adoption data and slow pressure on FDA timelines.